ClinicalTrials.gg
CompletedNCT01131624ASAPUpdated May 29, 2015

Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Women

A Phase 3 interventional study of ferrous sulphate and Ferinject in Anaemia, sponsored by Vifor Pharma. Completed at 20 sites in 5 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-05-29.

Sponsored by Vifor Pharma (part of CSL Limited) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
252
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing ferrous sulfate in Anemia — 2 open to participants now, 2 under way, none of them phase 3. ferrous sulfate · Anemia.

Enrollment
3rd of 23
252 · median 88
Started
2010
with 1 other
Phase 3
5 of 24
none open now
Registered
6th of 24
by date

Among the 24 studies testing ferrous sulfate in Anemia, this one is the 3rd largest by enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2010, is one of 5 in phase 3, and was the 6th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

2 of the 24 studies testing ferrous sulfate in Anemia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ferrous sulfate

ferrous sulfate: first FDA approval 1946 (FOLVRON). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing ferrous sulfate in Anemia, or all of them as a file.
02

Study summary

The purpose of this study is to look at how well Ferric Carboxymaltose, an intravenous iron therapy (iron that is infused directly into your body through a vein), compares with ferrous sulphate capsules taken by mouth in the treatment of iron deficiency anaemia during pregnancy.

Read the detailed description

This is an open-label, multicentre, randomised, 2-arm study to assess the efficacy and safety of FCM compared to oral iron in pregnant women with IDA.

During the screening period (Days -10 to 0 before randomisation), subjects will be selected based on eligibility criteria. Subjects who meet all of the inclusion criteria and none of the exclusion criteria will undergo baseline assessments at baseline (Day 0) prior to the first dose of study medication.

Subjects will be randomised to receive either intravenous (IV) iron (FCM, 1,000-1,500 mg) or oral iron (ferrous sulphate, 100 mg iron twice a day; total dose 200 mg/day).

The treatment period will begin with the infusion of FCM or the intake of oral iron on Day 0.

All subjects will return for assessment of efficacy and safety at Weeks 3, 6, 9, 12 and at delivery (or whichever comes first).

03

Conditions studied

  • Anaemia

Keywords

  • Iron deficiency
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnant women aged ≥18, gestational week ≥20, ≤33 at baseline visit with normal antenatal screening test results.
  • Iron deficiency anaemia defined as concentration ≥8 g/dl and ≤10.4 g/dL and serum ferritin ≤20 mcg/L at screening.
  • Demonstrated the ability to understand the requirements of the study, abide by the study restrictions, and agree to return for the required assessments. Patients (or their representative) must provide written for their participation in the study.

Exclusion criteria

Exclusion Criteria:

  • Blood transfusion, erythropoietin treatment, parenteral iron or oral iron treatment (1 month prior to screening) or anticipated need for a blood transfusion during the study.
  • Anaemia not caused by iron deficiency (e.g., aplastic, megaloblastic or haemolytic anaemia) or related to acute or ongoing, haemoglobinopathies, rheumatic and other chronic diseases, diseases, , bone marrow diseases, enzyme defects and drug induced anaemia.
  • Acute or chronic infection, active inflammatory disease (C-reactive protein >10 mg/dl or outside reference range), any acute infection at screening.
  • Pre-eclampsia.
  • Multiple pregnancy.
  • Evidence on any significant abnormalities on anomaly ultrasound.
  • Haemochromatosis or other iron storage disorders.
  • Folate deficiency (S-folate \<4.5 nmol/L) at screening.
  • Vitamin B12 deficiency (S-cobalamin \<145 pmol/L) at screening.
  • Serious medical condition, uncontrolled systemic disease or any other medical condition that, in the judgment of the Investigator, prohibits the patient from entering or potentially completing the study.
  • Known chronic renal failure (defined as \<30 mL/min calculated by Cockcroft-Gault or modification of diet in renal disease formula).
  • Severe cardiovascular diseases.
  • Known /acquired immunodeficiency syndrome, virus or virus infection.
  • Inability to fully comprehend and/or perform study procedures in the Investigator's opinion
  • History of endocrine disorders
  • Ongoing significant neurological or psychiatric disorders including psychotic disorders or dementia
  • Recent significant bleeding/surgery (within the 3 months prior to screening).
  • Chronic/acute hepatic disorder or elevating of liver enzymes (, alanine aminotransferase) over 2 times above the upper normal limit at screening.
  • Participation in any other interventional study since estimated conception and throughout study participation.
  • Known to FCM or other IV iron preparations.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
252 participants (actual)

Study arms

  • Active comparator
    Ferric carboxymaltose

    Subjects with bw ≥66 kg will receive an infusion of 1,000 mg iron as FCM and after 1 week a further 500 mg iron as FCM, depending on Hb at screening. subjects with bw \<66 kg, 2-3 infusions of 500 mg iron as FCM will be administered within 2 weeks from baseline, depending on Hb at screening

    Drug: Ferinject

  • Active comparator
    Oral Iron

    Oral Iron oral iron preparation will be provided at 200 mg iron per day in a convenient dosage schedule.

    Drug: ferrous sulphate

Interventions

  • 200 mg iron per day in a convenient dosage schedule.

    Also known as: Oral Iron

  • 1000-1500mg diluted only in sterile 0.9% sodium chloride, The maximum single dose of FCM that can be administered by intravenous infusion is 20 mL (1,000 mg iron) but should not exceed 15 mg of iron per kg of body weight. This means that for subjects with a bw below 66 kg a maximal dose of 500 mg iron per infusion is allowed.

    Also known as: Ferric carboxymaltose, FCM

06

What researchers measure

Primary outcomes

  1. Average Hb increase after 3 weeks in FCM compared to oral iron treated subjects (superiority).

    Time frame: 3 weeks after baseline

Secondary outcomes

  1. Change in Hb from baseline at Week 6

    Time frame: 6 weeks after baseline

  2. Change in Hb from baseline at Week 9

    Time frame: 9 weeks after baseline

  3. Change in Hb from baseline at Week 12

    Time frame: 12 weeks after baseline

07

Study locations

20 sites
  • The Northern Hospital
    Epping, Victoria 3076, Australia
  • Vivantes Klinikum Neukölln, Klinikum für Geburtsmedizin
    Berlin, 12351, Germany
  • Klinik Für Frauenheilkunde und Geburtshilfe Universitätsklinikum Marburg
    Marburg, 35043, Germany
  • Perinatalzentrum, Klinikum Innenstadt LMU
    München, 80337, Germany
  • Kvinnokliniken, Falu lasarett
    Falun, SE-791, Sweden
  • Kvinnokliniken, University Hospital
    Lund, SE-221, Sweden
  • Kvinnokliniken, Karolinska University Hospital
    Stockholm, 17176, Sweden
  • Karolinska Universitetssjukhuset Huddinge, Centrum för fostermedicin KK
    Stockholm, SE-141, Sweden
  • University Hospital, Dept of obstetrics and gynecology Uppsala
    Uppsala, SE-751, Sweden
  • Universitätsspital Basel, Geburtshilfe und Schwangerschaftsmedizin Frauenklinik
    Basel, 4031, Switzerland
  • Inselspital, Department of Obstetrics and Gynecology
    Bern, 3010, Switzerland
  • Humboldtstrasse
    Bern, 3013, Switzerland
  • HUG, Département de Gynécologie-Obstétrique
    Genève, 1211, Switzerland
  • CHUV, Département de Gynécologie-Obstétrique
    Lausanne, 1011, Switzerland
  • OR Lugano, sede Ospedale Civico, Clinica ginecologia ostetricia
    Lugano, 6900, Switzerland
  • Universitätsspital Zürich, Departement Frauenheilkunde
    Zürich, 8091, Switzerland
  • Cukurova University Hospital
    Adana, 01330, Turkey
  • Istanbul Uni. Ist. Med. Faculty
    Istanbul, 34093, Turkey
  • Zeynep Kamil Hospital, Arakiyeci Haci Mehmet Mahallesi.
    Istanbul, 34668, Turkey
  • Dr. Kutfi Kirdar Kartal Research and Education Hospital
    Istanbul, 34890, Turkey
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2010, a primary completion of May 2014 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2010
First posted
May 27, 2010
Start
May 2010
Primary completionActual
May 2014
CompletionActual
Apr 2015
Last update
May 29, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01131624
Lead sponsor
Vifor Pharma
Collaborators
Pierrel Research Europe GmbH
Responsible party
Sponsor
First posted
May 27, 2010
Start date
May 2010
Primary completion
May 2014
Completion
Apr 2015
Last update
May 29, 2015

Study contacts

Christian Breymann
principal investigator · University of Zurich

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ferrous sulfate · Ferric carboxymaltose

Start the discussion